Results 181 to 190 of about 13,555 (204)
Some of the next articles are maybe not open access.
JQ1, a Potential Therapeutic Molecule for Myeloid Leukemia with PTEN Deficiency
Blood, 2016Abstract Acute myeloid leukemia (AML) is a hematologic malignancy that continues to have high relapse and treatment-related mortality rates, despite recent advances in clinical management and therapy. Janus kinase (JAK) inhibitors inhibit the activity of the JAK/STAT pathway and have demonstrated some clinical responses in AML patients ...
Nicholas J Baltz +8 more
openaire +1 more source
The Minor Planet Electronic Circulars contain information on unusual minor planets, routine data on comets and natural satellites, and occasional editorial announcements. They are published on behalf of Division F of the International Astronomical Union by the Minor Planet Center, Smithsonian Astrophysical Observatory, Cambridge, MA 02138, U.S.A.
openaire +1 more source
openaire +1 more source
The Minor Planet Electronic Circulars contain information on unusual minor planets, routine data on comets and natural satellites, and occasional editorial announcements. They are published on behalf of Division F of the International Astronomical Union by the Minor Planet Center, Smithsonian Astrophysical Observatory, Cambridge, MA 02138, U.S.A.
openaire +1 more source
openaire +1 more source
The Minor Planet Electronic Circulars contain information on unusual minor planets, routine data on comets and natural satellites, and occasional editorial announcements. They are published on behalf of Division F of the International Astronomical Union by the Minor Planet Center, Smithsonian Astrophysical Observatory, Cambridge, MA 02138, U.S.A.
openaire +1 more source
openaire +1 more source
Bromodomain inhibitors, JQ1 and I-BET 762, as potential therapies for pancreatic cancer
Cancer Letters, 2017Bromodomain inhibitors (JQ1 and I-BET 762) are a new generation of selective, small molecule inhibitors that target BET (bromodomain and extra terminal) proteins. By impairing their ability to bind to acetylated lysines on histones, bromodomain inhibitors interfere with transcriptional initiation and elongation.
Ana S, Leal +5 more
openaire +2 more sources
Synergy between arsenic trioxide and JQ1 on autophagy in pancreatic cancer.
Oncogene, 2020Pancreatic cancer is a deadliest type of malignancy and lacks effective intervention. We here report a potential strategy for treatment of this malignancy by the combination of arsenic trioxide (ATO) and BET bromodomain inhibitor JQ1. These two agents synergistically modulate multistages of autophagy and thus induce apoptosis effectively in pancreatic ...
Congling, Xu +9 more
openaire +1 more source
Combination Therapy with the Epigenetic Drugs JQ1 and SAHA Inhibits PDAC
Cancer Discovery, 2015Abstract Dual inhibition of BET proteins and HDACs synergistically suppresses PDAC development and maintenance.
openaire +1 more source
T020 Targeting SALL4 by JQ1 in serous epithelial ovarian cancer
Clinica Chimica Acta, 2022Y. Wu, Y. Pei, K. Li, X. Lou, W. Cui
openaire +1 more source